Amundi
ACRS icon

Amundi’s Aclaris Therapeutics ACRS Stock Holding History

Amundi’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,975
Closed -$34.4K – 2027
2023
Q1 		$34.4K Hold
3,975
– – ﹤0.01% 1926
2022
Q4 		$65.7K Hold
3,975
– – ﹤0.01% 1663
2022
Q3 		$63K Buy
+3,975
New +$62.6K ﹤0.01% 1630

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amundi's ACRS Position: Q2 2023 in Review

Amundi sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 3,975 shares — an estimated $34.4K sold.

Amundi first reported a position in ACRS in Q3 2022 and held it in 3 quarters. The position peaked at $65.7K in Q4 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Amundi reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Amundi sold 3,975 Aclaris Therapeutics shares in Q2 2023, an estimated $34.4K.
  • Amundi first reported a position in Aclaris Therapeutics in Q3 2022 and held it in 3 quarters.
  • Amundi's Aclaris Therapeutics position peaked at $65.7K in Q4 2022.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Amundi's 13F filing for Q2 2023, filed 14 Aug 2023.